Converted by EDGARwiz

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and

documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity NOVOGEN LIMITED

ABN

37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the

director for the purposes of section 205G of the Corporations Act.

Name of Director

Graham Kelly

Date of last notice

3 June 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed

in this part.

Direct or indirect interest

Indirect

Nature of indirect interest

1. Bende Holdings Pty Ltd – controlled

(including registered holder)

entity

Note: Provide details of the circumstances giving rise to the relevant

_interest.

2. Coolawin Rd Pty Ltd – controlled

entity

3. Coolawin Rd Super Fund– controlled

entity

4. Phytose Corporation Pty Ltd –

controlled entity

Date of change

28 June 2013

No. of securities held prior to change

1. Bende Holdings Pty Ltd

1,677,343 ordinary shares

2. Coolawin Rd Pty Ltd

503,300 ordinary shares

3. Coolawin Rd Super Fund

10,354 ordinary shares

4. Phytose Corporation Pty Ltd

1,724,207 ordinary shares

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

Class

Fully Paid Ordinary Shares

Number acquired

1,800,000

Number disposed

Nil

Value/Consideration

$0.025

Note: If consideration is non-cash, provide details and estimated valuation

No. of securities held after change

1. Bende Holdings Pty Ltd

1,677,343 ordinary shares

2. Coolawin Rd Pty Ltd

503,300 ordinary shares

3. Coolawin Rd Super Fund

10,354 ordinary shares

4. Phytose Corporation Pty Ltd

3,524,207 ordinary shares

Nature of change

Part satisfaction of the purchase of the

Example: on-market trade, off-market trade, exercise of options, issue of

_{securities under dividend reinvestment plan, participation in buy-back}

shares in Triaxial Pharmaceuticals from

Phytose Corporation Pty Ltd

+ See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed

in this part.

Detail of contract

Convertible Notes

Nature of interest

Convertible Notes as approved at general meeting held

on 19 April 2013.

The terms of the Convertible Notes are as follows:

(1) The maximum value of the Convertible Notes is

$340,402 entitling the conversion to 13,616,085

Shares.

(2) The Convertible Notes may be exercised at the

holders discretion

(3) The convertible notes may not be converted until:

(a) Completion by the Company of a Phase Ia clinical

trial. Completion will be deemed to occur upon the

receipt of a signed study report

(b) Receipt by the Company of Investigational New

Drug status from the US Food and Drug

Administration.

trial or achieving Breakthrough Therapy

Designation. Completion will be deemed to occur

upon the receipt of a signed study report or

notification of the designation.

Name of registered holder

Phytose Corporation Pty Ltd

(if issued securities)

Date of change

28 June 2013

No. and class of securities to N/A

which interest related prior to

change

Note: Details are only required for a contract in relation

to which the interest has changed

Interest acquired

13,616,085 convertible notes

Interest disposed

N/A

Value/Consideration

Total Face value of $340,402 (ie $0.025 per convertible

Note: If consideration is non-cash, provide details and an

_{estimated valuation}

note).

Interest after change

13,616,085 convertible notes

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed No

above traded during a +closed period where prior

written clearance was required?

If so, was prior written clearance provided to allow the N/A

trade to proceed during this period?

If prior written clearance was provided, on what date N/A

was this provided?

+ See chapter 19 for defined terms.

Appendix 3Y Page 4

01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and

documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity NOVOGEN LIMITED

ABN

37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the

director for the purposes of section 205G of the Corporations Act.

Name of Director

Robert Howard Birch

Date of last notice

3 June 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed

in this part.

Direct or indirect interest

Direct

Indirect – Aquagolf Pty Limited <Aquagolf

Pty Ltd Superannuation Fund A/c>

Nature of indirect interest

(including registered holder)

Controlled entity

Note: Provide details of the circumstances giving rise to the relevant

interest.

Date of change

N/A

No. of securities held prior to change

Direct

124,986 Ordinary Shares

Aquagolf Pty Limited <Aquagolf Pty Ltd

S/F A/c>

1,497,136 Ordinary Shares

Class

N/A

Number acquired

N/A

Number disposed

N/A

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

Value/Consideration

N/A

Note: If consideration is non-cash, provide details and estimated valuation

No. of securities held after change

Direct

124,986 Ordinary Shares

Aquagolf Pty Limited <Aquagolf Pty Ltd

S/F A/c>

1,497,136 Ordinary Shares

Nature of change

N/A

Example: on-market trade, off-market trade, exercise of options, issue of

securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed

in this part.

Detail of contract

Convertible Notes

Nature of interest

Convertible Notes as approved at general meeting held

on 19 April 2013.

The terms of the Convertible Notes are as follows:

(1) The maximum value of the Convertible Notes is

$46,622 entitling the conversion to 1,864,864

Shares.

(2) The Convertible Notes may be exercised at the

holders discretion

(3) The convertible notes may not be converted until:

(a) Completion by the Company of a Phase Ia clinical

trial. Completion will be deemed to occur upon the

receipt of a signed study report

(b) Receipt by the Company of Investigational New

Drug status from the US Food and Drug

Administration.

trial or achieving Breakthrough Therapy

Designation. Completion will be deemed to occur

upon the receipt of a signed study report or

notification of the designation.

Name of registered holder

Aquagolf Pty Limited <Aquagolf Pty Ltd

(if issued securities)

Superannuation Fund A/c>

Date of change

28 June 2013

+ See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

No. and class of securities to N/A

which interest related prior to

change

Note: Details are only required for a contract in relation

to which the interest has changed

Interest acquired

1,864,864 convertible notes

Interest disposed

N/A

Value/Consideration

Total Face value of $46,622 (ie $0.025 per convertible

Note: If consideration is non-cash, provide details and an

_{estimated valuation}

note).

Interest after change

1,864,864 convertible notes

Part 3 – +Closed period

Were the interests in the securities or contracts detailed No

above traded during a +closed period where prior

written clearance was required?

If so, was prior written clearance provided to allow the N/A

trade to proceed during this period?

If prior written clearance was provided, on what date N/A

was this provided?

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and

documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity NOVOGEN LIMITED

ABN

37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the

director for the purposes of section 205G of the Corporations Act.

Name of Director

Andrew Heaton

Date of last notice

18 February 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed

in this part.

Direct or indirect interest

Direct

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant

interest.

Date of change

N/A

No. of securities held prior to change

7,600,400 Ordinary Shares

Class

N/A

Number acquired

N/A

Number disposed

N/A

Value/Consideration

N/A

Note: If consideration is non-cash, provide details and estimated valuation

No. of securities held after change

7,600,400 Ordinary Shares

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

Nature of change

N/A

Example: on-market trade, off-market trade, exercise of options, issue of

securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed

in this part.

Detail of contract

Convertible Notes

Nature of interest

Convertible Notes as approved at general meeting held

on 19 April 2013.

The terms of the Convertible Notes are as follows:

(1) The maximum value of the Convertible Notes is

$720,778 entitling the conversion to 28,831,101

Shares.

(2) The Convertible Notes may be exercised at the

holders discretion

(3) The convertible notes may not be converted until:

(a) Completion by the Company of a Phase Ia clinical

trial. Completion will be deemed to occur upon the

receipt of a signed study report

(b) Receipt by the Company of Investigational New

Drug status from the US Food and Drug

Administration.

trial

achieving

Breakthrough

Therapy

Designation. Completion will be deemed to occur

upon the receipt of a signed study report or

notification of the designation

Name of registered holder

Andrew Heaton

(if issued securities)

Date of change

28 June 2013

No. and class of securities to N/A

which interest related prior to

change

Note: Details are only required for a contract in relation

to which the interest has changed

Interest acquired

28,831,101 convertible notes

+ See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Interest disposed

N/A

Value/Consideration

Total Face value of $720,778 (ie $0.025 per convertible

Note: If consideration is non-cash, provide details and an

_{estimated valuation}

note).

Interest after change

28,831,101 convertible notes

Part 3 – +Closed period

Were the interests in the securities or contracts detailed No

above traded during a +closed period where prior

written clearance was required?

If so, was prior written clearance provided to allow the N/A

trade to proceed during this period?

If prior written clearance was provided, on what date N/A

was this provided?

+ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3